Literature DB >> 20947393

Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immunohistochemical study.

J H Kim1, K S Im, N H Kim, J Y Yhee, W G Nho, J H Sur.   

Abstract

HER-2 and HER-3 are transmembrane receptor proteins that are considered to be important but poorly understood biomarkers in canine tumors. In this study, the expression and the localization of HER-2 and HER-3 were evaluated immunohistochemically in canine mammary tumors (n=64; 12 benign, 52 malignant). HER-2 overexpression was identified in 2/12 (16.7%) benign and in 18/51 (35.3%) malignant cases. HER-3 was expressed in a non-nuclear localization in 11/12 (91.7%) benign and 18/52 (34.6%) malignant tumors. In contrast, HER-3 was expressed in the nucleus of neoplastic cells in 0/12 (0%) benign and 22/52 (42.3%) malignant tumors. Nuclear HER-3 expression was higher in neoplastic epithelial cells compared to myoepithelial cells, and positively correlated with high histological grade and lymphatic vessel invasion. These results suggest that nuclear HER-3 expression is significantly associated with tumor progression and metastasis and may serve as a useful prognostic biomarker in canine malignant mammary tumors.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20947393     DOI: 10.1016/j.tvjl.2010.08.012

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  10 in total

1.  Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer?

Authors:  G P Burrai; A Tanca; M R De Miglio; M Abbondio; S Pisanu; M Polinas; S Pirino; S I Mohammed; S Uzzau; M F Addis; E Antuofermo
Journal:  Tumour Biol       Date:  2015-06-19

2.  Correlation of tumor-infiltrating lymphocytes to histopathological features and molecular phenotypes in canine mammary carcinoma: A morphologic and immunohistochemical morphometric study.

Authors:  Jong-Hyuk Kim; Seung-Ki Chon; Keum-Soon Im; Na-Hyun Kim; Jung-Hyang Sur
Journal:  Can J Vet Res       Date:  2013-04       Impact factor: 1.310

3.  High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression.

Authors:  Elpetra P M Timmermans-Sprang; Ana Gracanin; Jan A Mol
Journal:  BMC Cancer       Date:  2015-07-25       Impact factor: 4.430

4.  ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).

Authors:  Dane A Hayes; Dale A Kunde; Robyn L Taylor; Stephen B Pyecroft; Sukhwinder Singh Sohal; Elizabeth T Snow
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

5.  Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.

Authors:  Frédérique Nguyen; Laura Peña; Catherine Ibisch; Delphine Loussouarn; Adelina Gama; Natascha Rieder; Anton Belousov; Mario Campone; Jérôme Abadie
Journal:  Breast Cancer Res Treat       Date:  2017-10-30       Impact factor: 4.872

6.  Cross-species oncogenic signatures of breast cancer in canine mammary tumors.

Authors:  Tae-Min Kim; In Seok Yang; Byung-Joon Seung; Sejoon Lee; Dohyun Kim; Yoo-Jin Ha; Mi-Kyoung Seo; Ka-Kyung Kim; Hyun Seok Kim; Jae-Ho Cheong; Jung-Hyang Sur; Hojung Nam; Sangwoo Kim
Journal:  Nat Commun       Date:  2020-07-17       Impact factor: 14.919

Review 7.  Current biomarkers of canine mammary tumors.

Authors:  Ilona Kaszak; Anna Ruszczak; Szymon Kanafa; Kamil Kacprzak; Magdalena Król; Piotr Jurka
Journal:  Acta Vet Scand       Date:  2018-10-29       Impact factor: 1.695

8.  Quantitative analysis of HER2 mRNA expression by RNA in situ hybridization in canine mammary gland tumors: Comparison with immunohistochemistry analysis.

Authors:  Byung-Joon Seung; Seung-Hee Cho; Soo-Hyeon Kim; Ha-Young Lim; Jung-Hyang Sur
Journal:  PLoS One       Date:  2020-02-14       Impact factor: 3.240

9.  Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccine.

Authors:  Judit Fazekas; Irene Fürdös; Josef Singer; Erika Jensen-Jarolim
Journal:  Oncol Lett       Date:  2016-08-11       Impact factor: 2.967

10.  Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.

Authors:  Xiao-Qian Dou; Hua Wang; Jing Zhang; Fang Wang; Gui-Li Xu; Cheng-Cheng Xu; Huan-Hua Xu; Shen-Si Xiang; Jie Fu; Hai-Feng Song
Journal:  Int J Nanomedicine       Date:  2018-02-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.